JP6537492B2 - 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法 - Google Patents

呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法 Download PDF

Info

Publication number
JP6537492B2
JP6537492B2 JP2016501801A JP2016501801A JP6537492B2 JP 6537492 B2 JP6537492 B2 JP 6537492B2 JP 2016501801 A JP2016501801 A JP 2016501801A JP 2016501801 A JP2016501801 A JP 2016501801A JP 6537492 B2 JP6537492 B2 JP 6537492B2
Authority
JP
Japan
Prior art keywords
rsv
antibody
antigen
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512554A (ja
JP2016512554A5 (enExample
Inventor
アン・ガーネット−バンダー
デーヴィッド・ペレズ−カバレロ
スマティ・シヴァパラシンガム
シュインバオ・ドワン
ダグラス・マクドナルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016512554A publication Critical patent/JP2016512554A/ja
Publication of JP2016512554A5 publication Critical patent/JP2016512554A5/ja
Application granted granted Critical
Publication of JP6537492B2 publication Critical patent/JP6537492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C07K16/11—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2016501801A 2013-03-14 2014-03-13 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法 Active JP6537492B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361782215P 2013-03-14 2013-03-14
US61/782,215 2013-03-14
US201361911093P 2013-12-03 2013-12-03
US61/911,093 2013-12-03
PCT/US2014/025259 WO2014159822A2 (en) 2013-03-14 2014-03-13 Human antibodies to respiratory syncytial virus f protein and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2016512554A JP2016512554A (ja) 2016-04-28
JP2016512554A5 JP2016512554A5 (enExample) 2017-03-30
JP6537492B2 true JP6537492B2 (ja) 2019-07-03

Family

ID=50391532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501801A Active JP6537492B2 (ja) 2013-03-14 2014-03-13 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法

Country Status (19)

Country Link
US (3) US9447173B2 (enExample)
EP (1) EP2968534B1 (enExample)
JP (1) JP6537492B2 (enExample)
KR (1) KR102211907B1 (enExample)
CN (1) CN105050622B (enExample)
AU (1) AU2014244411B2 (enExample)
BR (1) BR112015019066A2 (enExample)
CA (1) CA2904995A1 (enExample)
CL (1) CL2015002570A1 (enExample)
EA (1) EA034767B1 (enExample)
IL (1) IL240067A0 (enExample)
MX (1) MX360253B (enExample)
MY (1) MY174772A (enExample)
PH (1) PH12015501558B1 (enExample)
SG (2) SG11201505338RA (enExample)
TW (1) TWI659968B (enExample)
UY (1) UY35416A (enExample)
WO (1) WO2014159822A2 (enExample)
ZA (1) ZA201504952B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN107206069A (zh) 2014-10-10 2017-09-26 埃博灵克斯股份有限公司 Rsv感染的治疗
CA2963030C (en) 2014-10-10 2021-07-13 Vectura Gmbh Inhalation device for use in aerosol therapy of respiratory diseases
US9340604B1 (en) * 2014-10-29 2016-05-17 Aridis Pharmaceuticals, Inc. Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
US20180171125A1 (en) 2015-06-25 2018-06-21 Sabic Global Technologies B.V. Polymer composition comprising linear low-density polyethylene
KR20180074654A (ko) * 2015-07-02 2018-07-03 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염의 치료를 위한 조성물 및 방법
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
SG11201903287PA (en) * 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503843A (ja) 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR20250041082A (ko) 2017-07-06 2025-03-25 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
EP3695003A4 (en) * 2017-10-13 2021-12-22 Adimab, LLC ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND METHOD OF GENERATING AND USING THEREOF
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
MX2020008062A (es) * 2018-01-31 2020-12-03 Wistar Inst Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.
JP7349998B2 (ja) 2018-01-31 2023-09-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
MY202358A (en) 2018-03-19 2024-04-24 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
EP3774841A1 (en) 2018-08-27 2021-02-17 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CA3100038A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
WO2020061560A1 (en) * 2018-09-21 2020-03-26 The University Of North Carolina At Chapel Hill Synthetic binding agents for limiting permeation through mucus
CN110016079B (zh) * 2018-12-18 2019-12-24 珠海泰诺麦博生物技术有限公司 抗呼吸道合胞病毒的中和抗体及其应用
BR112021009543A2 (pt) 2019-01-16 2021-08-17 Regeneron Pharmaceuticals, Inc. métodos para identificar tióis livres em um medicamento de proteína, de identificação de heterogeneidade de dissulfeto em um medicamento de proteína e para selecionar um medicamento de proteína, e, composição farmacêutica
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
PH12022550630A1 (en) 2019-09-24 2023-03-27 Regeneron Pharma Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
US12239687B2 (en) 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
AU2022209730A1 (en) 2021-01-20 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
BR112023017442A2 (pt) 2021-03-03 2023-09-26 Regeneron Pharma Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
KR20230162932A (ko) 2021-03-26 2023-11-29 리제너론 파아마슈티컬스, 인크. 혼합 프로토콜 개발을 위한 방법 및 시스템
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
EP4405390A1 (en) 2021-09-20 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
IL312372A (en) 2021-10-26 2024-06-01 Regeneron Pharma Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
KR20240164561A (ko) 2022-03-18 2024-11-19 리제너론 파아마슈티컬스, 인크. 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
JP2026500269A (ja) 2022-12-16 2026-01-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーカラムの完全性を評価するための方法及びシステム
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1994006448A1 (en) 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2230127A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
AR030019A1 (es) 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
EP1259547B1 (en) 2000-03-01 2012-07-11 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2006041970A2 (en) 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
KR20080113223A (ko) 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US7736648B2 (en) 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
WO2010087927A2 (en) * 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
PL2464664T3 (pl) 2009-08-13 2016-02-29 Crucell Holland Bv Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
US20110097358A1 (en) 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
CN102850454B (zh) * 2011-09-27 2014-06-25 上海博沃生物科技有限公司 抗呼吸道合胞病毒的人单克隆抗体
DK2828293T3 (en) 2012-03-20 2018-01-08 Humabs Biomed S A ANTIBODIES NEUTRALIZING RSV, MPV AND PVM AND USE THEREOF
JP6450688B2 (ja) 2013-02-01 2019-01-09 メディミューン，エルエルシー 呼吸器合胞体ウイルスｆタンパク質エピトープ
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US10047145B2 (en) 2013-07-24 2018-08-14 Humabs Biomed Sa Antibodies that potently neutralize RSV and uses thereof

Also Published As

Publication number Publication date
BR112015019066A2 (pt) 2017-08-22
CL2015002570A1 (es) 2016-07-29
TWI659968B (zh) 2019-05-21
SG11201505338RA (en) 2015-08-28
MX2015009416A (es) 2015-10-05
WO2014159822A3 (en) 2015-01-08
UY35416A (es) 2014-10-31
ZA201504952B (en) 2016-07-27
KR20150129668A (ko) 2015-11-20
EP2968534B1 (en) 2019-02-27
PH12015501558A1 (en) 2015-09-21
AU2014244411B2 (en) 2018-04-19
US9447173B2 (en) 2016-09-20
KR102211907B1 (ko) 2021-02-05
US10125188B2 (en) 2018-11-13
MY174772A (en) 2020-05-14
SG10201610336QA (en) 2017-01-27
TW201444866A (zh) 2014-12-01
EP2968534A2 (en) 2016-01-20
MX360253B (es) 2018-10-26
WO2014159822A2 (en) 2014-10-02
AU2014244411A1 (en) 2015-08-20
NZ710829A (en) 2021-01-29
JP2016512554A (ja) 2016-04-28
US20170029488A1 (en) 2017-02-02
IL240067A0 (en) 2015-09-24
PH12015501558B1 (en) 2019-02-06
CN105050622A (zh) 2015-11-11
CN105050622B (zh) 2018-10-23
US20140271653A1 (en) 2014-09-18
HK1220372A1 (en) 2017-05-05
EA034767B1 (ru) 2020-03-18
EA201591771A1 (ru) 2016-06-30
US20190031741A1 (en) 2019-01-31
CA2904995A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
JP6537492B2 (ja) 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法
US12116401B2 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US20250388653A1 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US12215141B2 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
RU2779105C2 (ru) Антитела к респираторно-синцитиальному вирусу и способы их получения и применения
HK1220372B (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
NZ710829B2 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190604

R150 Certificate of patent or registration of utility model

Ref document number: 6537492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250